Filtered By:
Condition: Coronary Heart Disease
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 806 results found since Jan 2013.

Contrasting Cholesterol Management Guidelines for Adults with CKD
In conclusion, these guidelines show high concordance for statin treatment for adults with CKD.
Source: Journal of the American Society of Nephrology : JASN - April 30, 2015 Category: Urology & Nephrology Authors: Colantonio, L. D., Baber, U., Banach, M., Tanner, R. M., Warnock, D. G., Gutierrez, O. M., Safford, M. M., Wanner, C., Howard, G., Muntner, P. Tags: Clinical Epidemiology Source Type: research

Abstract 146: Clinical and Economic Consequences of Statin Intolerance in the U.S.: Results from an Integrated Health System Session Title: Poster Session I
Conclusion: While the majority of SI patients were on a statin, SI patients demonstrate a higher risk of some cardiovascular events; incur higher healthcare costs; and difficulty reaching LDL-C goals compared to patients without SI. Alternative treatment strategies are needed to better serve this at-risk patient population.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Sanchez, R. J., Graham, J. H., Evans, M. A., Mallya, U. G., Panaccio, M. P., Steinhubl, S. R. Tags: Session Title: Poster Session I Source Type: research

Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.
CONCLUSIONS: This meta-analysis suggests that the use of statins in CKD for primary prevention of cardiovascular disease is effective. These findings are consistent with recent guidance for the use of statins in all patients with CKD. PMID: 25833405 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 1, 2015 Category: Urology & Nephrology Authors: Major RW, Cheung CK, Gray LJ, Brunskill NJ Tags: Clin J Am Soc Nephrol Source Type: research

Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy The TNT Trial
ConclusionsElevated OxPL-apoB levels predict secondary MACE in patients with stable CHD, a risk that is mitigated by atorvastatin 80 mg. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691)
Source: Journal of the American College of Cardiology - March 30, 2015 Category: Cardiology Source Type: research

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States Coronary Heart Disease
Conclusions In patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for long-term secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding. Clinical Trial Registration URL: clinicaltrials.gov Unique Identifier: NCT00526474.
Source: JAHA:Journal of the American Heart Association - March 19, 2015 Category: Cardiology Authors: Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., Nicolau, J. C., Oude Ophuis, T., Scirica, B. M., Spinar, J., Theroux, P., Morrow, D. A. Tags: Coronary Heart Disease Source Type: research

High dose atorvastatin therapy yields a better carotid atherosclerosis improvement in Chinese patients
Statins is one of key components in the cocktail of medications for the treatment of patients with atherosclerosis and have proved to reduce vascular events significantly in primary and secondary prevention of coronary heart disease (CHD) in the past decades [1–3]. As the most widely used statins, the effectiveness of atorvastatin in lowering LDL-C has been demonstrated in several trials [4,5]. Plasma LDL-C levels and carotid intima-media thickness (IMT) have been proved associated with incidence of stroke [6].
Source: International Journal of Cardiology - March 11, 2015 Category: Cardiology Authors: Yafeng Li, Shoucui Gao, Yingfeng An, Enqi Liu, Sihai Zhao Source Type: research

The new Pooled Cohort Equations Risk Calculator
Publication date: Available online 4 February 2015 Source:Canadian Journal of Cardiology Author(s): David Preiss , Søren L. Kristensen In the NCEP ATPIII guidelines published in 2001, estimation of cardiovascular risk was recommended based on the Framingham score for ten year risk of myocardial infarction while the Canadian Cardiovascular Society currently recommends the Framingham total cardiovascular risk score. During development of joint guidelines released in 2013 by the American College of Cardiology (ACC) and American Heart Association (AHA), the decision was taken to develop a new risk score. This resulted in th...
Source: Canadian Journal of Cardiology - February 6, 2015 Category: Cardiology Source Type: research

Why You Should Avoid Statins
At my anti-aging clinic, I continue to wage war against what I call the “medical-industrial complex.” And I do it for one reason only – I care more about my patients than I do about profits. Big Pharma clearly takes the opposite view. And now it seems these pharmaceutical behemoths won’t be happy until every man, woman and child is popping anti-cholesterol pills. Researchers at Duke University recently issued a report recommending that even children and people as young as 30 should be on statins, if they have just slightly elevated cholesterol levels.1 And why wouldn’t researchers at Duke recommen...
Source: Al Sears, MD Natural Remedies - February 3, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Heart Health Source Type: news

Biomarkers of progression in diabetic nephropathy – the past, present and future
This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - January 1, 2015 Category: Endocrinology Authors: CH Lee, KSL Lam Tags: Editorial Source Type: research

Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003-2012.
Authors: Gu Q, Paulose-Ram R, Burt VL, Kit BK Abstract KEY FINDINGS: Data from the National Health and Nutrition Examination Survey. During 2003-2012, the percentage of adults aged 40 and over using a cholesterol-lowering medication in the past 30 days increased from 20% to 28%. The use of statins increased from 18% to 26%. By 2011-2012, 93% of adults using a cholesterol-lowering medication used a statin. Cholesterol-lowering medication use increased with age, from 17% of adults aged 40-59 to 48% of adults aged 75 and over. About 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia ...
Source: NCHS data brief - December 29, 2014 Category: American Health Tags: NCHS Data Brief Source Type: research

Treatment of dyslipidemia.
Authors: Tonkin A, Byrnes A Abstract Atherosclerotic cardiovascular disease (including coronary heart disease, stroke and peripheral arterial disease) is the leading cause of death globally. Abnormal blood lipids (dyslipidemia), smoking, and high blood pressure are responsible for more than 75% of cases. Aggressive low-density lipoprotein (LDL)-cholesterol lowering therapy, particularly statins, appear to be the most effective of the therapeutic approaches, but even with their use, cardiovascular disease event rates remain relatively high, underpinning the quest for novel treatments. In this review we discuss recen...
Source: F1000 Medicine Reports - December 1, 2014 Category: Biomedical Science Tags: F1000Prime Rep Source Type: research

Vascular Ultrasound Imaging for Screening Patients at Risk for Cardiovascular Events
Carotid intima-media thickness (IMT) has been proposed as a useful predictor of cardiovascular (CV) events in asymptomatic subjects in prospective observational studies, and has been used as a surrogate marker of efficacy in randomized therapeutic trials of statins [1]. Furthermore, meta-analyses have demonstrated incremental coronary heart disease and stroke risk prediction with IMT [2]. The evidence emerging from numerous observational, interventional, and meta-analytical studies led, at the AHA Prevention Conference V, to the recommendation of the use of “carefully performed carotid ultrasound in experienced laborator...
Source: CVD Prevention and Control - December 1, 2014 Category: Cardiology Authors: Tasneem Z. Naqvi Tags: Editorial Comment Source Type: research

Statins in neurological disorders: An overview and update
Publication date: October 2014 Source:Pharmacological Research, Volume 88 Author(s): Anna Maria Malfitano , Giuseppe Marasco , Maria Chiara Proto , Chiara Laezza , Patrizia Gazzerro , Maurizio Bifulco Statins have, at present, the potential to provide a new therapeutic target for various neurological diseases. It is well established that statins reduce cholesterol levels and prevent coronary heart disease. Moreover, evidence suggest that statins have additional properties such as endothelial protection via action on the nitric oxide synthase system as well as antioxidant, anti-inflammatory and anti-platelet effects. Thes...
Source: Pharmacological Research - November 6, 2014 Category: Drugs & Pharmacology Source Type: research

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Publication date: Available online 7 August 2014 Source:American Heart Journal Author(s): Gregory G. Schwartz , Laurence Bessac , Lisa G. Berdan , Deepak L. Bhatt , Vera Bittner , Rafael Diaz , Shaun G. Goodman , Corinne Hanotin , Robert A. Harrington , J. Wouter Jukema , Kenneth W. Mahaffey , Angèle Moryusef , Robert Pordy , Matthew T. Roe , Tyrus Rorick , William J. Sasiela , Cheerag Shirodaria , Michael Szarek , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Philippe Gabriel Steg Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to le...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial Clinical Sciences
Conclusions— This post hoc analysis suggests that atorvastatin treatment may improve renal function in patients with prior stroke or transient ischemic attack with and without chronic kidney disease, and that atorvastatin treatment may prevent eGFR decline in patients with stroke and diabetes mellitus. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00147602.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Amarenco, P., Callahan, A., Campese, V. M., Goldstein, L. B., Hennerici, M. G., Messig, M., Sillesen, H., Welch, K. M. A., Wilson, D. J., Zivin, J. A. Tags: Lipids, Secondary prevention, Cerebrovascular disease/stroke Clinical Sciences Source Type: research